Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

atment. PEGASYS is also contraindicated in hepatic decompensation with Child-Pugh score greater than or equal to 6 in cirrhotic CHC patients coinfected with HIV before or during treatment. PEGASYS is also contraindicated in neonates and infants because it contains benzyl alcohol. Benzyl alcohol is associated with an increased incidence of neurological and other complications in neonates and infants, which are sometimes fatal. PEGASYS and COPEGUS therapy is additionally contraindicated in patients with a hypersensitivity to COPEGUS or any of its components, in women who are pregnant, men whose female partners are pregnant, and patients with hemoglobinopathies (eg, thalassemia major, sickle-cell anemia).

COPEGUS THERAPY SHOULD NOT BE STARTED UNLESS A REPORT OF A NEGATIVE PREGNANCY TEST HAS BEEN OBTAINED IMMEDIATELY PRIOR TO INITIATION OF THERAPY. Women of childbearing potential and men must use two forms of effective contraception during treatment and during the 6 months after treatment has concluded. Routine monthly pregnancy tests must be performed during this time. If pregnancy should occur during treatment or during 6 months post-therapy, the patient must be advised of the significant teratogenic risk of COPEGUS therapy to the fetus. Healthcare providers and patients are strongly encouraged to immediately report any pregnancy in a patient or partner of a patient during treatment or during 6 months after treatment cessation to the Ribavirin Pregnancy Registry at 1-800-593-2214.

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS. During treatment, patients' clinical status and hepatic function should be closely monitored, and PEGASYS treatment should be immediately discontinued if decompensation (Child-Pugh score greater than or equal to 6) is observed.

The most common adverse events reported for PEGASYS and COPEGUS combination therapy observed
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... N.C. , Aug. 28, 2015  Delays ... research projects can slow down the decision-making process, ... is, therefore, absolutely critical for biopharmaceutical companies to ... research approval process for quicker and more meaningful ... by Best Practices, LLC, nearly three-quarters of benchmarked ...
(Date:8/28/2015)... Research and Markets ... the "12th Annual Report and Survey of ... their offering. The 2015 12th Annual ... Production is the most recent study of biotherapeutic ... future capacity and production. The report contains the ...
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/rktnl9/investigation ... "Investigation Report on China,s Insulin Aspart Market, 2010-2019" ... by Novo Nordisk, insulin aspart (under the trade ... the treatment of diabetes. Compared with human insulin, ... starts working fast and reports higher peak of ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... No Malaria Day at the Zoo to celebrate children helping children, a thank ... their congregations throughout West Ohio have contributed to the United Methodist initiative to ...
(Date:8/28/2015)... ... 28, 2015 , ... With the goal of furthering music education programs in ... the Adams County Fairgrounds in Mendon, IL on May 30th, 2015. Backed once again ... education in the underfunded school districts of Mendon and its neighboring town of Quincy, ...
(Date:8/28/2015)... ... August 28, 2015 , ... As reported by Medical Daily on August ... for results that last for two years, the longest of any cellulite reduction system ... looking for a long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, ...
(Date:8/28/2015)... ... August 28, 2015 , ... Loved ones of a person ... with chemical dependency, may be able to find some hope in the latest ... center for addiction located in Western Michigan. Focusing on several different aspects of ...
(Date:8/28/2015)... ... 2015 , ... Altima Technologies, Inc., the maker of popular ... assets and audio-video devices, recently released Visio Stencils for the following product lines: ... EMC VNX Series , Super Micro Computer SuperStorage, Hitachi Data Systems Virtual Storage ...
Breaking Medicine News(10 mins):Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3
... - Two current members step down to become ... a leading provider of wireless, handheld barcode ... that Ms. Margaret Laub, Chief Executive Officer of ... joined the IntelliDOT Board of Directors. (Logo: ...
... finisher adds large aluminum anodizing capacity to their electroplating, anodizing, and ... ... 2009 -- Team Metal Finishing announced the completion of their new ... said, "The project has been in the works for some time ...
... Whether finding will lead to treatment improvements remains unclear ... study of the effects of genetics on blood pressure ... control levels of salt in the body with high ... and stroke. , "There have been hundreds of genes ...
... 16 The Healthcare Group at Frost & Sullivan,is ... on the,European Cardiac Rhythm Management Market to be held ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ... the leading cause of premature death on a,global scale ...
... Measuring 40mm X 28mm, the new 1611RL fixed blade axial dc ... , ... Chatsworth, CA (Vocus) February 16, 2009 -- ... X 28mm fixed blade axial dc fan, specifically designed to offer ...
... NEW YORK, Feb. 15 The American Psychoanalytic Association ... their staffs for including strong privacy protections for mental ... American Recovery and Reinvestment Act of 2009. At a ... houses, jobs and health insurance has been deeply shaken ...
Cached Medicine News:Health News:Margaret Laub Appointed to IntelliDOT Board of Directors 2Health News:Margaret Laub Appointed to IntelliDOT Board of Directors 3Health News:Margaret Laub Appointed to IntelliDOT Board of Directors 4Health News:Genes That Control Body's Salt Levels Are Identified 2Health News:Genes That Control Body's Salt Levels Are Identified 3Health News:Global Economic Meltdown - Is the European Cardiac Rhythm Management Market Spared? 2Health News:Global Economic Meltdown - Is the European Cardiac Rhythm Management Market Spared? 3Health News:New Fixed Blade Axial dc Fan From NMB 2Health News:Psychoanalysts Laud Members of Congress for Inclusion of Privacy Protections in Stimulus Bill 2
Reagent Basin, 60mL, 5/Box...
Reservoir, 8 Well, 10/Box...
... manually adjustable dispensing head, and disposable, pre-sterilized ... cost-efficiency to microplate fluid dispensing. It is ... offer fast dispensing of fluids in a ... It also offers the added benefit of ...
The WellPro 384 is designed for use with 384 well microplates. It utilizes a 24 channel liquid head and can perform serial dilutions in a 16 or 24 across format, and plate to plate transfers and plat...
Medicine Products: